Identifying a novel locus for psoriatic arthritis

被引:14
|
作者
Budu-Aggrey, Ashley [1 ,2 ,3 ]
Bowes, John [1 ]
Barton, Anne [1 ,2 ,3 ,4 ]
机构
[1] Univ Manchester, Arthrit Res UK Ctr Genet & Genom, Manchester M13 9PT, Lancs, England
[2] Cent Manchester Fdn Trust, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci, Manchester M13 9PT, Lancs, England
[4] Cent Manchester Fdn Trust, NIHR Manchester Biomed Res Ctr, Kellgren Ctr Rheumatol, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Psoriatic arthritis; psoriasis; specific risk loci; Immunochip; functional characterization; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; METHOTREXATE; VARIANTS; EFFICACY; PHASE-3; PTPN22;
D O I
10.1093/rheumatology/kev273
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A number of studies have identified genetic risk loci for PsA, the majority of which also confer risk for psoriasis. The stronger heritability of PsA in comparison with psoriasis suggests that there should be risk loci that are specific for PsA. Identifying such loci could potentially inform therapy development to provide more effective treatments for PsA patients, especially with a considerable proportion being non-responsive to current therapies. Evidence of a PsA-specific locus has been previously found at HLA-B27 within the MHC region. A recent study has provided evidence of non-HLA risk loci that are specific for PsA at IL23R, PTPN22 and on chromosome 5q31. Functional characterization of these loci will provide further understanding of the pathways underlying PsA, and enable us to apply genetic findings for patient benefit.
引用
收藏
页码:25 / 32
页数:8
相关论文
共 50 条
  • [31] Methotrexate in psoriatic arthritis
    Pertuiset, Edouard
    JOINT BONE SPINE, 2014, 81 (02) : 107 - 109
  • [32] Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis
    Krathen, Michael S.
    Gottlieb, Alice B.
    Mease, Philip J.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (11) : 2205 - 2215
  • [33] Therapy of psoriatic arthritis
    Maerker-Hermann, E.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (08): : 784 - +
  • [34] Tofacitinib in psoriatic arthritis
    Wang, Ting-Shun
    Tsai, Tsen-Fang
    IMMUNOTHERAPY, 2017, 9 (14) : 1153 - 1163
  • [35] Power of crowdsourcing: Novel methods of data collection in psoriasis and psoriatic arthritis
    Armstrong, April W.
    Harskamp, Caitlin T.
    Cheeney, Safia
    Wu, Julie
    Schupp, Clayton W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (06) : 1273 - U278
  • [36] Infliximab in Psoriatic Arthritis
    Cantini, Fabrizio
    Niccoli, Laura
    Nannini, Carlotta
    Kaloudi, Olga
    Cassara, Emanuele
    JOURNAL OF RHEUMATOLOGY, 2012, 39 : 71 - 73
  • [37] Psoriatic arthritis: current therapy and future directions
    DoQuyen Huynh
    Kavanaugh, Arthur
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (13) : 1755 - 1764
  • [38] Psoriatic arthritis: tissue-directed inflammation?
    Cafaro, Giacomo
    McInnes, Iain B.
    CLINICAL RHEUMATOLOGY, 2018, 37 (04) : 859 - 868
  • [39] Treatment of psoriatic arthritis. Are there differential indications?
    Koehm, M.
    Behrens, F.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (01): : 23 - 32
  • [40] Apremilast in the treatment of psoriatic arthritis: a perspective review
    Reed, Michael
    Crosbie, David
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2017, 9 (02) : 45 - 53